{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:16:04Z","timestamp":1793146564358,"version":"4.5.0"},"reference-count":71,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T00:00:00Z","timestamp":1611878400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J GEN INTERN MED"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s11606-020-06504-8","type":"journal-article","created":{"date-parts":[[2021,1,29]],"date-time":"2021-01-29T17:02:58Z","timestamp":1611939778000},"page":"2074-2084","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":121,"title":["Cannabidiol Interactions with Medications, Illicit Substances, and Alcohol: a Comprehensive Review"],"prefix":"10.1007","volume":"36","author":[{"given":"Premalatha","family":"Balachandran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Elsohly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0143-8739","authenticated-orcid":false,"given":"Kevin P.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,29]]},"reference":[{"issue":"5","key":"6504_CR1","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.lfs.2005.09.011","volume":"78","author":"MA ElSohly","year":"2005","unstructured":"ElSohly MA, Slade D. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life Sci 2005;78(5):539-548.","journal-title":"Life Sci"},{"key":"6504_CR2","unstructured":"Joy JE, Watson S, Benson J. Marijuana and Medicine. Assessing the Science Base. 1999:1999."},{"key":"6504_CR3","unstructured":"Mikulic M. Global Pharmaceutical Industry\u2013Statistics & Facts. In: Statista; 2019."},{"issue":"6","key":"6504_CR4","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1111\/epi.12631","volume":"55","author":"O Devinsky","year":"2014","unstructured":"Devinsky O, Cilio MR, Cross H, et al. Cannabidiol: pharmacology and potential therapeutic role in epilepsy and other neuropsychiatric disorders. Epilepsia. 2014;55(6):791-802.","journal-title":"Epilepsia."},{"key":"6504_CR5","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.pharmthera.2017.02.041","volume":"175","author":"S Pisanti","year":"2017","unstructured":"Pisanti S, Malfitano AM, Ciaglia E, et al. Cannabidiol: state of the art and new challenges for therapeutic applications. Pharmacol Ther 2017;175:133-150.","journal-title":"Pharmacol Ther"},{"key":"6504_CR6","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.phrs.2016.01.033","volume":"112","author":"AC Campos","year":"2016","unstructured":"Campos AC, Foga\u00e7a MV, Sonego AB, Guimar\u00e3es FS. Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res 2016;112:119-127.","journal-title":"Pharmacol Res"},{"issue":"3-4","key":"6504_CR7","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/0014-2999(82)90264-3","volume":"83","author":"P Consroe","year":"1982","unstructured":"Consroe P, Benedito MA, Leite JR, Carlini EA, Mechoulam R. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. Eur J Pharmacol 1982;83(3-4):293-298.","journal-title":"Eur J Pharmacol"},{"key":"6504_CR8","doi-asserted-by":"crossref","unstructured":"Coimbra N, Mendes-Gomes J, Da Silva J, Dos Anjos-Garcia T, Ullah F, Almada R. New Ethological and Morphological Perspectives for the Investigation of Panicolytic-Like Effects of Cannabidiol. In: Handbook of Cannabis and Related Pathologies. Elsevier; 2017:e140-e149.","DOI":"10.1016\/B978-0-12-800756-3.00098-3"},{"key":"6504_CR9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.pnpbp.2015.06.017","volume":"64","author":"AP Schiavon","year":"2016","unstructured":"Schiavon AP, Bonato JM, Milani H, Guimar\u00e3es FS, de Oliveira RMW. Influence of single and repeated cannabidiol administration on emotional behavior and markers of cell proliferation and neurogenesis in non-stressed mice. Prog Neuro-Psychopharmacol Biol Psychiatry 2016;64:27-34.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"issue":"5-6","key":"6504_CR10","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.lfs.2011.05.018","volume":"89","author":"R Jiang","year":"2011","unstructured":"Jiang R, Yamaori S, Takeda S, Yamamoto I, Watanabe K. Identification of cytochrome P450 enzymes responsible for metabolism of cannabidiol by human liver microsomes. Life Sci 2011;89(5-6):165-170.","journal-title":"Life Sci"},{"key":"6504_CR11","doi-asserted-by":"crossref","unstructured":"Jiang R, Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol is a potent inhibitor of the catalytic activity of cytochrome P450 2C19. Drug Metabolism and Pharmacokinetics. 2013:DMPK-12-RG-129.","DOI":"10.2133\/dmpk.DMPK-12-RG-129"},{"issue":"3","key":"6504_CR12","doi-asserted-by":"publisher","first-page":"206","DOI":"10.2174\/1389200217666151210142051","volume":"17","author":"O Zendulka","year":"2016","unstructured":"Zendulka O, Dovrtelov\u00e1 G, Noskov\u00e1 K, et al. Cannabinoids and cytochrome P450 interactions. Curr Drug Metab 2016;17(3):206-226.","journal-title":"Curr Drug Metab"},{"issue":"7","key":"6504_CR13","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.bcp.2005.07.007","volume":"70","author":"TM Bland","year":"2005","unstructured":"Bland TM, Haining RL, Tracy TS, Callery PS. CYP2C-catalyzed delta (9)-tetrahydrocannabinol metabolism: kinetics, pharmacogenetics and interaction with phenytoin. Biochem Pharmacol 2005;70(7):1096-1103.","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"6504_CR14","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1111\/epi.13060","volume":"56","author":"AL Geffrey","year":"2015","unstructured":"Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug\u2013drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia. 2015;56(8):1246-1251.","journal-title":"Epilepsia."},{"issue":"4","key":"6504_CR15","doi-asserted-by":"publisher","first-page":"237","DOI":"10.2174\/157488611798280924","volume":"6","author":"M Machado Bergamaschi","year":"2011","unstructured":"Machado Bergamaschi M, Helena Costa Queiroz R, Waldo Zuardi A, Crippa AS. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf 2011;6(4):237-249.","journal-title":"Curr Drug Saf"},{"key":"6504_CR16","unstructured":"Monographie N. Cannabidiol. Deutscher Arzneimittel-Codex (DAC) inkl Neues Rezeptur-Formularium (NRF) DAC\/NRF October. 2015;22."},{"key":"6504_CR17","doi-asserted-by":"crossref","unstructured":"Wedman-St Louis B. 14 Drug Interactions & Dosing Issues. Cannabis as Medicine. 2019.","DOI":"10.1201\/9780429054723"},{"issue":"7","key":"6504_CR18","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1073\/pnas.0711278105","volume":"105","author":"JE Lauckner","year":"2008","unstructured":"Lauckner JE, Jensen JB, Chen H-Y, Lu H-C, Hille B, Mackie K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci 2008;105(7):2699-2704.","journal-title":"Proc Natl Acad Sci"},{"issue":"13","key":"6504_CR19","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1073\/pnas.1211204110","volume":"110","author":"S Sylantyev","year":"2013","unstructured":"Sylantyev S, Jensen TP, Ross RA, Rusakov DA. Cannabinoid-and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses. Proc Natl Acad Sci 2013;110(13):5193-5198.","journal-title":"Proc Natl Acad Sci"},{"issue":"42","key":"6504_CR20","doi-asserted-by":"publisher","first-page":"11229","DOI":"10.1073\/pnas.1711351114","volume":"114","author":"JS Kaplan","year":"2017","unstructured":"Kaplan JS, Stella N, Catterall WA, Westenbroek RE. Cannabidiol attenuates seizures and social deficits in a mouse model of Dravet syndrome. Proc Natl Acad Sci 2017;114(42):11229-11234.","journal-title":"Proc Natl Acad Sci"},{"key":"6504_CR21","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.153","volume":"1","author":"V Feinshtein","year":"2013","unstructured":"Feinshtein V, Erez O, Ben-Zvi Z, et al. Cannabidiol changes P-gp and BCRP expression in trophoblast cell lines. PeerJ. 2013;1:e153.","journal-title":"PeerJ."},{"key":"6504_CR22","unstructured":"Database MC. https:\/\/reference.medscape.com\/drug-interactionchecker Accessed March 28 2020."},{"issue":"3","key":"6504_CR23","doi-asserted-by":"publisher","first-page":"833","DOI":"10.3390\/ijms19030833","volume":"19","author":"S Zou","year":"2018","unstructured":"Zou S, Kumar U. Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system. Int J Mol Sci 2018;19(3):833.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"6504_CR24","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1089\/can.2016.0034","volume":"2","author":"K Iffland","year":"2017","unstructured":"Iffland K, Grotenhermen F. An update on safety and side effects of cannabidiol: a review of clinical data and relevant animal studies. Cannabis Cannabinoid Res 2017;2(1):139-154.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"4","key":"6504_CR25","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1097\/j.pain.0000000000001464","volume":"160","author":"T van de Donk","year":"2019","unstructured":"van de Donk T, Niesters M, Kowal MA, Olofsen E, Dahan A, van Velzen M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain. 2019;160(4):860.","journal-title":"Pain."},{"issue":"2","key":"6504_CR26","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1080\/15622975.2017.1285049","volume":"20","author":"JM Khoury","year":"2019","unstructured":"Khoury JM, Neves MdCLd, Roque MAV, et al. Is there a role for cannabidiol in psychiatry? World J Biol Psychiatry 2019;20(2):101-116.","journal-title":"World J Biol Psychiatry"},{"key":"6504_CR27","unstructured":"Database DB. https:\/\/www.drugbank.ca\/drugs\/DB09061\/biointeractions#target-tab Accessed April 15 2020."},{"issue":"3","key":"6504_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/BF00421539","volume":"37","author":"G Chesher","year":"1974","unstructured":"Chesher G, Jackson DM. Anticonvulsant effects of cannabinoids in mice: drug interactions within cannabinoids and cannabinoid interactions with phenytoin. Psychopharmacologia. 1974;37(3):255-264.","journal-title":"Psychopharmacologia."},{"issue":"1","key":"6504_CR29","first-page":"26","volume":"201","author":"P Consroe","year":"1977","unstructured":"Consroe P, Wolkin A. Cannabidiol--antiepileptic drug comparisons and interactions in experimentally induced seizures in rats. J Pharmacol Exp Ther 1977;201(1):26-32.","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"6504_CR30","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/clpt.1980.139","volume":"28","author":"NL Benowitz","year":"1980","unstructured":"Benowitz NL, Nguyen TL, Jones RT, Herning RI, Bachman J. Metabolic and psychophysiologic studies of cannabidiol-hexobarbital interaction. Clin Pharmacol Ther 1980;28(1):115-120.","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"6504_CR31","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1124\/dmd.111.041384","volume":"39","author":"S Yamaori","year":"2011","unstructured":"Yamaori S, Okamoto Y, Yamamoto I, Watanabe K. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 2011;39(11):2049-2056.","journal-title":"Drug Metab Dispos"},{"key":"6504_CR32","doi-asserted-by":"publisher","first-page":"589","DOI":"10.3851\/IMP1953","volume":"17","author":"M Naccarato","year":"2012","unstructured":"Naccarato M, Yoong D, Kovacs C, Gough K. Case report a case of a potential drug interaction between clobazam and etravirine-based antiretroviral therapy. Antivir Ther 2012;17:589-592.","journal-title":"Antivir Ther"},{"issue":"11","key":"6504_CR33","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1124\/dmd.32.11.1279","volume":"32","author":"C Giraud","year":"2004","unstructured":"Giraud C, Tran A, Rey E, Vincent J, Tr\u00e9luyer J-M, Pons G. In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. Drug Metab Dispos 2004;32(11):1279-1286.","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"6504_CR34","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1002\/j.1875-9114.2012.01028.x","volume":"32","author":"M Walzer","year":"2012","unstructured":"Walzer M, Bekersky I, Blum RA, Tolbert D. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes. Pharmacotherapy 2012;32(4):340-353.","journal-title":"Pharmacotherapy"},{"issue":"8","key":"6504_CR35","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1002\/cpdd.665","volume":"8","author":"G Morrison","year":"2019","unstructured":"Morrison G, Crockett J, Blakey G, Sommerville K. A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev 2019;8(8):1009-1031.","journal-title":"Clin Pharmacol Drug Dev"},{"key":"6504_CR36","unstructured":"Grotenhermen F, Gebhardt K, Berger M. Cannabidiol. Solothurn, Schweiz: Nachtschatten Verlag 2016:17-63."},{"issue":"11","key":"6504_CR37","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1007\/s11910-018-0882-y","volume":"18","author":"TE Gaston","year":"2018","unstructured":"Gaston TE, Szaflarski JP. Cannabis for the treatment of epilepsy: an update. Curr Neurol Neurosci Rep 2018;18(11):73.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"8","key":"6504_CR38","first-page":"500","volume":"29","author":"PF Consroe","year":"1977","unstructured":"Consroe PF, AL Wolkin Anticonvulsant interaction of cannabidiol and ethosuximide in rats. J Pharm Pharmacol 1977;29(8):500-501.","journal-title":"J Pharm Pharmacol"},{"issue":"5","key":"6504_CR39","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1002\/ptr.2625","volume":"23","author":"C Scuderi","year":"2009","unstructured":"Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G. Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders. Phytotherapy Res 2009;23(5):597-602.","journal-title":"Phytotherapy Res"},{"issue":"9","key":"6504_CR40","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1111\/epi.13852","volume":"58","author":"TE Gaston","year":"2017","unstructured":"Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP, Program UC. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia. 2017;58(9):1586-1592.","journal-title":"Epilepsia."},{"key":"6504_CR41","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.yebeh.2019.07.008","volume":"98","author":"TE Gaston","year":"2019","unstructured":"Gaston TE, Bebin EM, Cutter GR, et al. Drug\u2013drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program. Epilepsy Behav 2019;98:201-206.","journal-title":"Epilepsy Behav"},{"key":"6504_CR42","doi-asserted-by":"publisher","first-page":"107733","DOI":"10.1016\/j.neuropharm.2019.107733","volume":"158","author":"K Soca\u0142a","year":"2019","unstructured":"Soca\u0142a K, Wyska E, Szafarz M, Nieoczym D, Wla\u017a P. Acute effect of cannabidiol on the activity of various novel antiepileptic drugs in the maximal electroshock-and 6 Hz-induced seizures in mice: Pharmacodynamic and pharmacokinetic studies. Neuropharmacology. 2019;158:107733.","journal-title":"Neuropharmacology."},{"issue":"1","key":"6504_CR43","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1089\/can.2015.0012","volume":"1","author":"I Ujv\u00e1ry","year":"2016","unstructured":"Ujv\u00e1ry I, Hanu\u0161 L. Human metabolites of cannabidiol: a review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res 2016;1(1):90-101.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"1","key":"6504_CR44","first-page":"11","volume":"4","author":"H P\u0103unescu","year":"2011","unstructured":"P\u0103unescu H, Coman O, Coman L, et al. Cannabinoid system and cyclooxygenases inhibitors. J Med Life 2011;4(1):11.","journal-title":"J Med Life"},{"key":"6504_CR45","doi-asserted-by":"publisher","first-page":"S296","DOI":"10.1016\/j.euroneuro.2019.09.430","volume":"29","author":"A Gasparyan","year":"2019","unstructured":"Gasparyan A, Navarrete F, Manzanares J. P. 417 Effects of cannabidiol and sertraline on behavioral and neurochemical alterations induced by a new long-lasting animal model of PTSD. Eur Neuropsychopharmacol. 2019;29:S296.","journal-title":"Eur Neuropsychopharmacol"},{"key":"6504_CR46","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pnpbp.2018.06.002","volume":"86","author":"AJ Sales","year":"2018","unstructured":"Sales AJ, Crestani CC, Guimar\u00e3es FS, Joca SR. Antidepressant-like effect induced by Cannabidiol is dependent on brain serotonin levels. Prog Neuro-Psychopharmacol Biol Psychiatry 2018;86:255-261.","journal-title":"Prog Neuro-Psychopharmacol Biol Psychiatry"},{"key":"6504_CR47","doi-asserted-by":"crossref","unstructured":"Wilson-Morkeh H, Al-Abdulla A, Sien L, Mohamed H, Youngstein T. Important drug interactions exist between cannabidiol oil and commonly prescribed drugs in rheumatology practice. Rheumatology. 2020.","DOI":"10.1093\/rheumatology\/kez304"},{"issue":"3","key":"6504_CR48","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/FBP.0000000000000119","volume":"26","author":"H Neelakantan","year":"2015","unstructured":"Neelakantan H, Tallarida RJ, Reichenbach ZW, Tuma RF, Ward SJ, Walker EA. Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice. Behav Pharmacol 2015;26(3):304-314.","journal-title":"Behav Pharmacol"},{"key":"6504_CR49","doi-asserted-by":"publisher","first-page":"108914","DOI":"10.1016\/j.cbi.2019.108914","volume":"316","author":"Y Qian","year":"2020","unstructured":"Qian Y, Gilliland TK, Markowitz JS. The influence of carboxylesterase 1 polymorphism and cannabidiol on the hepatic metabolism of heroin. Chem Biol Interact 2020;316:108914.","journal-title":"Chem Biol Interact"},{"issue":"3","key":"6504_CR50","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1097\/ADM.0000000000000118","volume":"9","author":"AF Manini","year":"2015","unstructured":"Manini AF, Yiannoulos G, Bergamaschi MM, et al. Safety and pharmacokinetics of oral cannabidiol when administered concomitantly with intravenous fentanyl in humans. J Addict Med 2015;9(3):204.","journal-title":"J Addict Med"},{"key":"6504_CR51","doi-asserted-by":"crossref","unstructured":"ElSohly MA, Radwan MM, Gul W, Chandra S, Galal A. Phytochemistry of Cannabis sativa L. In: Phytocannabinoids. Springer; 2017:1-36.","DOI":"10.1007\/978-3-319-45541-9_1"},{"issue":"3","key":"6504_CR52","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/BF00432554","volume":"76","author":"AW Zuardi","year":"1982","unstructured":"Zuardi AW, Shirakawa I, Finkelfarb E, Karniol I. Action of cannabidiol on the anxiety and other effects produced by \u0394 9-THC in normal subjects. Psychopharmacology. 1982;76(3):245-250.","journal-title":"Psychopharmacology."},{"issue":"1","key":"6504_CR53","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1038\/npp.2017.209","volume":"43","author":"DL Boggs","year":"2018","unstructured":"Boggs DL, Nguyen JD, Morgenson D, Taffe MA, Ranganathan M. Clinical and preclinical evidence for functional interactions of cannabidiol and \u0394 9-tetrahydrocannabinol. Neuropsychopharmacology. 2018;43(1):142-154.","journal-title":"Neuropsychopharmacology."},{"issue":"3","key":"6504_CR54","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1038\/npp.2009.184","volume":"35","author":"S Bhattacharyya","year":"2010","unstructured":"Bhattacharyya S, Morrison PD, Fusar-Poli P, et al. Opposite effects of \u0394-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology. 2010;35(3):764-774.","journal-title":"Neuropsychopharmacology."},{"issue":"17","key":"6504_CR55","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1111\/bph.13887","volume":"174","author":"KM King","year":"2017","unstructured":"King KM, Myers AM, Soroka-Monzo AJ, et al. Single and combined effects of \u03949-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br J Pharmacol 2017;174(17):2832-2841.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"6504_CR56","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1111\/bph.13333","volume":"173","author":"S Todd","year":"2016","unstructured":"Todd S, Arnold J. Neural correlates of interactions between cannabidiol and \u03949-tetrahydrocannabinol in mice: implications for medical cannabis. Br J Pharmacol 2016;173(1):53-65.","journal-title":"Br J Pharmacol"},{"issue":"9","key":"6504_CR57","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1038\/npp.2010.58","volume":"35","author":"CJ Morgan","year":"2010","unstructured":"Morgan CJ, Freeman TP, Schafer GL, Curran HV. Cannabidiol attenuates the appetitive effects of \u0394 9-tetrahydrocannabinol in humans smoking their chosen cannabis. Neuropsychopharmacology. 2010;35(9):1879-1885.","journal-title":"Neuropsychopharmacology."},{"issue":"2","key":"6504_CR58","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.euroneuro.2016.12.004","volume":"27","author":"SM Todd","year":"2017","unstructured":"Todd SM, Zhou C, Clarke DJ, Chohan TW, Bahceci D, Arnold JC. Interactions between cannabidiol and \u03949-THC following acute and repeated dosing: Rebound hyperactivity, sensorimotor gating and epigenetic and neuroadaptive changes in the mesolimbic pathway. Eur Neuropsychopharmacol 2017;27(2):132-145.","journal-title":"Eur Neuropsychopharmacol"},{"issue":"11","key":"6504_CR59","doi-asserted-by":"publisher","first-page":"2477","DOI":"10.1111\/bcp.13710","volume":"84","author":"CJ Lucas","year":"2018","unstructured":"Lucas CJ, Galettis P, Schneider J. The pharmacokinetics and the pharmacodynamics of cannabinoids. Br J Clin Pharmacol 2018;84(11):2477-2482.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"6504_CR60","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/bcpt.13152","volume":"124","author":"P Damkier","year":"2019","unstructured":"Damkier P, Lassen D, Christensen MMH, Madsen KG, Hellfritzsch M, Potteg\u00e5rd A. Interaction between warfarin and cannabis. Basic Clin Pharmacol Toxicol 2019;124(1):28-31.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"10","key":"6504_CR61","doi-asserted-by":"publisher","first-page":"2944","DOI":"10.1111\/ajt.15398","volume":"19","author":"AD Leino","year":"2019","unstructured":"Leino AD, Emoto C, Fukuda T, Privitera M, Vinks AA, Alloway RR. Evidence of a clinically significant drug-drug interaction between cannabidiol and tacrolimus. Am J Transplant 2019;19(10):2944-2948.","journal-title":"Am J Transplant"},{"issue":"7","key":"6504_CR62","doi-asserted-by":"publisher","first-page":"989","DOI":"10.3390\/jcm8070989","volume":"8","author":"JD Brown","year":"2019","unstructured":"Brown JD, Winterstein AG. Potential adverse drug events and drug\u2013drug interactions with medical and consumer Cannabidiol (CBD) use. J Clin Med 2019;8(7):989.","journal-title":"J Clin Med"},{"issue":"12","key":"6504_CR63","doi-asserted-by":"publisher","first-page":"2256","DOI":"10.3390\/molecules24122256","volume":"24","author":"LE Ewing","year":"2019","unstructured":"Ewing LE, McGill MR, Yee EU, et al. Paradoxical Patterns of Sinusoidal Obstruction Syndrome-Like Liver Injury in Aged Female CD-1 Mice Triggered by Cannabidiol-Rich Cannabis Extract and Acetaminophen Co-Administration. Molecules. 2019;24(12):2256.","journal-title":"Molecules."},{"key":"6504_CR64","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.nbd.2016.06.013","volume":"94","author":"M dos-Santos-Pereira","year":"2016","unstructured":"dos-Santos-Pereira M, da-Silva CA, Guimaraes FS, Del-Bel E. Co-administration of cannabidiol and capsazepine reduces L-DOPA-induced dyskinesia in mice: possible mechanism of action. Neurobiol Dis 2016;94:179-195.","journal-title":"Neurobiol Dis"},{"issue":"1612","key":"6504_CR65","doi-asserted-by":"publisher","first-page":"20120431","DOI":"10.1098\/rstb.2012.0431","volume":"368","author":"DW Nebert","year":"2013","unstructured":"Nebert DW, Wikvall K, Miller WL. Human cytochromes P450 in health and disease. Philos Transact R Soc B: Biol Sci 2013;368(1612):20120431.","journal-title":"Philos Transact R Soc B: Biol Sci"},{"issue":"15-16","key":"6504_CR66","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.lfs.2011.02.017","volume":"88","author":"S Yamaori","year":"2011","unstructured":"Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K. Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 2011;88(15-16):730-736.","journal-title":"Life Sci"},{"issue":"4","key":"6504_CR67","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1037\/pha0000272","volume":"27","author":"CN Nona","year":"2019","unstructured":"Nona CN, Hendershot CS, Le Foll B. Effects of cannabidiol on alcohol-related outcomes: A review of preclinical and human research. Exp Clin Psychopharmacol 2019;27(4):359.","journal-title":"Exp Clin Psychopharmacol"},{"key":"6504_CR68","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.freeradbiomed.2013.12.026","volume":"68","author":"L Yang","year":"2014","unstructured":"Yang L, Rozenfeld R, Wu D, Devi LA, Zhang Z, Cederbaum A. Cannabidiol protects liver from binge alcohol-induced steatosis by mechanisms including inhibition of oxidative stress and increase in autophagy. Free Radic Biol Med 2014;68:260-267.","journal-title":"Free Radic Biol Med"},{"issue":"2","key":"6504_CR69","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1124\/jpet.105.085779","volume":"314","author":"C Hamelink","year":"2005","unstructured":"Hamelink C, Hampson A, Wink DA, Eiden LE, Eskay RL. Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. J Pharmacol Exp Ther 2005;314(2):780-788.","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"6504_CR70","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/0165-0173(93)90013-P","volume":"18","author":"TE Robinson","year":"1993","unstructured":"Robinson TE, Berridge KC. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res Rev 1993;18(3):247-291.","journal-title":"Brain Res Rev"},{"issue":"1","key":"6504_CR71","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/BF00431988","volume":"66","author":"P Consroe","year":"1979","unstructured":"Consroe P, Carlini EA, Zwicker AP, Lacerda LA. Interaction of cannabidiol and alcohol in humans. Psychopharmacology. 1979;66(1):45-50.","journal-title":"Psychopharmacology."}],"container-title":["Journal of General Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11606-020-06504-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11606-020-06504-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,28]],"date-time":"2023-01-28T20:19:11Z","timestamp":1674937151000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11606-020-06504-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,29]]},"references-count":71,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["6504"],"URL":"https:\/\/doi.org\/10.1007\/s11606-020-06504-8","relation":{},"ISSN":["0884-8734","1525-1497"],"issn-type":[{"value":"0884-8734","type":"print"},{"value":"1525-1497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,29]]},"assertion":[{"value":"6 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}